Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shenghui Tang

Showing results (11-20 of 118) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Overestimation of the effect size in group sequential trialsJenny J Zhang, Gideon M Blumenthal, Kun He, et al.
Journal of Molecular Histology|January 6, 2026
Upregulation of MYBL2 ameliorates senescence of nucleus pulposus cells in degenerative intervertebral discs based on RNA-sequencing analysisShenghui Tang, Tao Liu, Lixue Wu, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 19, 2016
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder CancerJonathan Jarow, V Ellen Maher, Shenghui Tang, et al.
AIDS Research and Human Retroviruses|March 6, 2004
HLA allele sharing and HIV type 1 viremia in seroconverting Zambians with known transmitting partnersJianming Tang, Shenghui Tang, Elena Lobashevsky, et al.
The Oncologist|December 15, 2010
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)Martin H Cohen, John R Johnson, Somesh Chattopadhyay, et al.
Therapeutic Innovation & Regulatory Science|September 20, 2018
Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysisJenny J Zhang, Huanyu Chen, Kun He, et al.
The Oncologist|July 28, 2012
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumorsGideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, et al.
The Oncologist|April 26, 2019
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular RemissionE Dianne Pulte, Tanya Wroblewski, Erik Bloomquist, et al.
BMC Musculoskeletal Disorders|November 16, 2021
Single-stage debridement via autogenous iliac bone graft through the OLIF corridor and lateral fixation in treating spontaneous single-level lumbar pyogenic spondylodiscitisSongsong Wu, Bin Lin, Xi Li, et al.
The Oncologist|February 25, 2017
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker AnalysisJames Xunhai Xu, V Ellen Maher, Lijun Zhang, et al.
Pageof 12

Showing results (11-20 of 118) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Overestimation of the effect size in group sequential trialsJenny J Zhang, Gideon M Blumenthal, Kun He, et al.
Journal of Molecular Histology|January 6, 2026
Upregulation of MYBL2 ameliorates senescence of nucleus pulposus cells in degenerative intervertebral discs based on RNA-sequencing analysisShenghui Tang, Tao Liu, Lixue Wu, et al.
Bladder Cancer (Amsterdam, Netherlands)|April 19, 2016
Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder CancerJonathan Jarow, V Ellen Maher, Shenghui Tang, et al.
AIDS Research and Human Retroviruses|March 6, 2004
HLA allele sharing and HIV type 1 viremia in seroconverting Zambians with known transmitting partnersJianming Tang, Shenghui Tang, Elena Lobashevsky, et al.
The Oncologist|December 15, 2010
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)Martin H Cohen, John R Johnson, Somesh Chattopadhyay, et al.
Therapeutic Innovation & Regulatory Science|September 20, 2018
Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysisJenny J Zhang, Huanyu Chen, Kun He, et al.
The Oncologist|July 28, 2012
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumorsGideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, et al.
The Oncologist|April 26, 2019
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular RemissionE Dianne Pulte, Tanya Wroblewski, Erik Bloomquist, et al.
BMC Musculoskeletal Disorders|November 16, 2021
Single-stage debridement via autogenous iliac bone graft through the OLIF corridor and lateral fixation in treating spontaneous single-level lumbar pyogenic spondylodiscitisSongsong Wu, Bin Lin, Xi Li, et al.
The Oncologist|February 25, 2017
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker AnalysisJames Xunhai Xu, V Ellen Maher, Lijun Zhang, et al.
Pageof 12